Finerenone is now approved for heart failure with LVEF ≥40%, expanding treatment options for this growing patient group with poor prognosis. The FINEARTS-HF trial showed finerenone significantly ...
Finerenone was associated with a 16% reduction for the primary composite endpoint of cardiovascular death and total HF events compared with placebo. The Food and Drug Administration (FDA) has accepted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results